Skip to main content

Table 2 Adverse events

From: Adjunctive tonic motor activation enables opioid reduction for refractory restless legs syndrome: a prospective, open-label, single-arm clinical trial

 

Number (%) of Participants

All AEs

Device-related AEs

Any AE

14 (70%)

11 (55%)

Serious AE

0

0

AE severity

 Grade 1

14 (70%)

11 (55%)

 Grade 2 or higher

0

0

MedDRA preferred term

 Discomfort

9 (45%)

9 (45%)

 Restless Legs Syndrome

7 (35%)

1 (5%)

 Skin irritation

2 (10%)

2 (10%)

 Drug withdrawal syndrome

2 (10%)

0

 COVID-19

2 (10%)

0

  1. MedDRA preferred terms occurring in more than 1 participant are shown
  2. AE adverse event, MedDRA Medical Dictionary for Regulatory Activities
Back to article page

BMC Neurology

ISSN: 1471-2377

Contact us